Lung Tumor Protein Synthesis Rates in Lung Cancer Patients

NCT05794529 | Recruiting DMC

• 1 other identifier: METCZ20220060
• Study Type: observational
• Target: 30
• Locations: 1 country
• Sites: 1

Brief Summary

The current study will recruit lung cancer patients to measure tissue protein synthesis rates of non-small cell lung carcinomas and healthy lung tissue. The protein synthesis rates of healthy lung tissue will be compared to lung tumor tissue to establish the remodeling characteristics of healthy versus cancerous lung tissues. We will also examine whether tissue protein synthesis rates of non-small cell lung carcinomas are associated with various tumor- (i.e., size, subclassification) and patient-derived (i.e., inflammation, lung function, smoking status, and smoking history) parameters.

Conditions

Lung Cancer

Outcome Measures

Primary Outcomes (3)

• Lung tumor fractional synthetic rate

  units: % per day

  5 days prior to surgery

• Lung tissue fractional synthetic rate

  units: % per day

  5 days prior to surgery

• Muscle tissue fractional synthetic rate

  units: % per day

  5 days prior to surgery

Secondary Outcomes (11)

• Plasma glucose concentrations

  Baseline

• Plasma insulin concentrations

  Baseline

• Plasma GH concentrations

  Baseline

• Plasma IGF-1 concentrations

  Baseline

• Plasma IGFBP-1 concentrations

  Baseline

Study Arms (1)

Lung cancer patient

Lung cancer patients diagnosed a non-small cell lung carcinoma requiring resection surgery.

Other: There are no interventions in the present study

Interventions

There are no interventions in the present study OTHER

There are no interventions in the present study

Lung cancer patient

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

In total, we will recruit 30 lung cancer patients (diagnosed with a NSCLC) scheduled to undergo surgery. The nature and the risks of the experimental procedures will be explained to all subjects before their informed consent will be obtained. All subjects will be recruited through contact with their Surgeon at the Department of surgery at Zuyderland Medical Centre, Heerlen.

You may qualify if:

• Aged 18-65 years
• Compos mentis
• Diagnosed with lung cancer, with treatment requiring a thoracotomy or VATS lobectomy

You may not qualify if:

• Neoadjuvant chemo- or radiotherapy in the past four weeks
• Use of systemic steroids in the past four week
• Insulin-dependent diabetes mellitus
• Pregnancy

Sponsors & Collaborators

• Maastricht University Medical Center: lead

Study Sites (1)

Zuyderland Medical Center

Heerlen, Limburg, 6419 PC, Netherlands

RECRUITING

MeSH Terms

Conditions

Lung Neoplasms

Condition Hierarchy (Ancestors)

Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Diseases

Central Study Contacts

Andrew Holwerda, PhD

CONTACT

+31433881381; andy.holwerda@maastrichtuniversity.nl

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: OTHER
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 15, 2023
• First Posted: April 3, 2023
• Study Start: March 1, 2023
• Primary Completion: March 1, 2026
• Study Completion: March 1, 2026
• Last Updated: April 3, 2023

Record last verified: 2023-03

Data Sharing

• IPD Sharing: Will not share

Locations

NL (1)